SHORT MINI-FUTURE - GENMAB | Market Closed - Deutsche Boerse AG 14:04:45 2024-05-17 EDT | ||
| 29.26 EUR | -0.14% |
|
| 1 month | -1.55% | ||
| 3 months | -2.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 29.26 | -0.14% |
| 24-05-16 | 29.3 | +1.24% |
| 24-05-15 | 28.94 | -2.49% |
| 24-05-14 | 29.68 | +0.03% |
| 24-05-13 | 29.67 | -0.87% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:04 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VV9WME |
| ISIN | DE000VV9WME9 |
| Date issued | 2022-11-17 |
| Strike | 4,239 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.27 € |
|---|---|
| Lowest since issue | 12.59 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,041
DKK
Average target price
2,470
DKK
Spread / Average Target
+21.01%
- Stock Market
- Certificates
- Certificat
